Sedentary Behavior in U.S. Adults Declined in Last Decade
However, prevalence remained similar through 2023
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
Strong outcomes seen in terms of weight loss, with lower doses of semaglutide used
FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
GLP-1 receptor agonists are associated with improvements in restrained eating, emotional eating behavior, QOL
Risk for Death, MACE Increased for Patients With Adult-Onset Type 1 Diabetes
Risk for MACE lower in adult-onset T1D versus T2D, but mortality higher from diabetic coma or ketoacidosis
Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
Findings for matched groups of patients with obesity and diabetes taking first-generation GLP-1 RA or undergoing bariatric metabolic surgery
Age-, Sex-, Race-Specific Standards for Thyroid Diseases May Reclassify Many Patients
In a recent study, a number of persons with subclinical hypothyroidism were reclassified as normal, especially women and White participants
Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis
Risk for postoperative eKA slightly increased; lower risks seen for perioperative acute kidney injury and 30-day mortality
GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity
Reductions in alcohol intake noted in high and low consumers; no significant difference seen in percentage reductions for men and women
